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PURPOSE: The probability of colorectal cancer is moder-
ately increased among carriers of the APC I1307K polymor-
phism. However, it is not known if endoscopic surveillance
of this high-risk group is warranted. The prevalence of pol-
yps and adenomas in specimens of colorectal cancer who
are carriers and noncarriers of the APC I1307K polymor-
phism is compared. METHOD: Prevalence of adenomatous
polyps in the pathology specimens of the study partici-
pants, stratified by their APC I1307K polymorphism status,
was studied in 900 consecutive cases of colorectal cancer
diagnosed in northern Israel between 1998 and 2002,
within the framework of a population-based, case-
controlled study (MECC Study). RESULTS: The APC I1307K
mutation was detected in 78 colorectal cancer cases (8.7
percent) of the study population. Prevalence was higher
among Ashkenazi Jews (11.2 percent) than among non-
Ashkenazi Jews (2.7 percent) or Arabs (3.1 percent). After
adjustment for age, APC I1307K carriers were significantly
more likely than noncarriers to have polyps in their surgical
specimen (51.3 percent vs. 32.6 percent, P = 0.002). Ade-
nomas with a tubular component (either tubular adenomas
or tubulovillous adenomas), but not villous adenomas, were
significantly more frequent among carriers (37.2 percent vs.
23.6 percent, P = 0.005). CONCLUSION: Together with
former evidence of I1307K being a risk factor for colorectal
cancer, these data suggest that colonoscopic surveillance
for colorectal adenomas and cancer may be warranted in
I1307K carriers, even in the absence of other identifiable
risk factors. [Key words: Colorectal cancer; Israel; Epidemi-
ology; APC I1307K; Adenoma]
A n isoleucine-to-lysine polymorphism at codon1307 (I1307K) of the APC gene creating a hyper-
mutable area and predisposing the development of
carcinoma has been identified in 6 to 7 percent of the
Ashkenazi Jews.1 Several studies have confirmed that
the magnitude of risk of colorectal cancer conferred
by this polymorphism is approximately 1.8 times the
risk among noncarriers.2–8 Some have looked at this
polymorphism with regard to other disease groups
such as inflammatory bowel disease9 and multiple ad-
enomas.10–11 APC I1307K does not account for the
increased risk of colorectal cancer in patients with
inflammatory bowel disease, but it appears to be
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overrepresented among individuals with multiple ad-
enomas.
High-risk groups have been shown to benefit from
enhanced colorectal surveillance,12 and thus it would
be useful to evaluate the potential for screening
I1307K carriers. A strong relationship between APC
I1307K and colorectal adenomas would provide a ra-
tionale for considering enhanced surveillance within
this group, especially if the adenomas demonstrated
advanced histologic features suggesting further
pathogenetic evolution of these clonal colorectal pro-
liferations. Thus, additional studies of APC I1307K
and adenomas are warranted.
The current report studies the prevalence of ade-
nomas in I1307K carriers to evaluate if routine endo-
scopic surveillance may be of value for this group.
MATERIALS AND METHODS
Cases from the Molecular Epidemiology of Colorec-
tal Cancer (MECC) study, an institutional review
board (IRB)-approved, ongoing, population-based,
case-controlled study in northern Israel, were in-
cluded. All cases were diagnosed between 1998 and
2002 with invasive cancer of the colon or rectum and
underwent a surgical procedure, usually a hemicolec-
tomy. Study tools used after the patient signed an
informed consent, include full interview, blood
sample, tumor blocks, and frozen tumors. All eligible
cases were evaluated for the presence of the I1307K
polymorphism in the APC gene. APC I1307K carriers
were identified by allele-specific oligohybridization as
previously described.13 Histologic diagnosis of inva-
sive colorectal cancer was independently confirmed
by a single external GI pathologist (JKG). Pathology
reports were reviewed for any mention of polyps or
adenomas in the surgical specimen. The number of
polyps and their histologic characteristics (hyperplas-
tic, tubular, tubulovillous, villous) were recorded. All
pathology reports from the five participating hospitals
were written by a single pathologist in each hospital.
Two of the five involved hospital pathologists read
more than 70 percent of the slides in this study. The
interpreting pathologist was usually not the same pa-
thologist who received and described the surgical
specimen. All pathologists and the data extractors
were blinded as to the APC I1307K carrier status of the
case.
Age-adjusted prevalence rates and 95 percent con-
fidence intervals of polyps in the various demo-
graphic groups were calculated (using the age distri-
bution of all Jews in the study as the standard
population) and compared using Z-test. Comparisons
of proportion with polyps between carriers and non-
carriers were conducted using the chi-squared test.
Univariate analysis of variance (ANOVA) was used for
testing differences in mean number of polyps, ad-
justed for age. Level of significance for all tests was set
at P  0.05. Data analysis was performed using SPSS
V. 11.5 (SPSS Inc., Chicago, IL).
RESULTS
This interim analysis pertains to 900 cases of colo-
rectal cancer diagnosed in northern Israel within a
framework of a population-based, case-controlled
study. Of these, 78 cases (8.7 percent) were found to
carry the I1307K polymorphism. Much higher preva-
lence of the polymorphism was noted among Jews
(9.3 percent) than among colorectal cancer cases of
Arab descent (3.1 percent). Ashkenazi Jews with co-
lorectal cancer had a much higher prevalence (11.2
percent) than non-Ashkenazi Jewish cases (2.7 per-
cent) (Table 1).
Prevalence of Polyps
APC I1307K carriers were significantly more likely
than noncarriers to have any polyps in their surgical
specimen after age-adjustment (51.3 percent vs. 33.6
percent, P = 0.03). The higher prevalence of any pol-
yps was found in Ashkenazi and non-Ashkenazi Jew-
ish carriers alike (Table 2). This excess was noted in
males and females and also in Arab patients, although
Table 1.
Prevalence of I1307K Polymorphism Among MECC







Jews 817 76 9.3
Ashkenazi 633 71 11.2
Males 331 35 10.6
Females 302 36 11.9
Non-Ashkenazi 184 5 2.7
Males 94 4 4.3
Females 90 1 1.1
Arabs 65 2 3.1
Males 36 1 2.8
Females 29 1 3.4
Non-Jewish /
Non-Arab 14 0 0
Total 896 78 8.7
MECC = Molecular Epidemiology of Colorectal Cancer.
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it did not reach statistical significance in these sub-
groups (data not shown).
Number and Type of Polyps
The mean number of polyps per surgical specimen
(excluding those where no polyps were found) did
not differ significantly between APC I1307K carriers
and noncarriers, in either Ashkenazi Jews (2.47 vs.
2.75) or non-Ashkenazi Jews (2.60 vs. 2.31), when
tested in a model, which included age.
Among the adenomas, villous adenomas were not
found to differ significantly in prevalence between the
carriers and noncarriers, but adenomas with a tubular
component (either tubular adenomas or tubulovillous
adenomas) were significantly more frequent among
all carriers and Jewish carriers, mostly attributed to
their higher prevalence in non-Ashkenazi Jews (Ta-
ble 3).
No differences were appreciated when analyses
were restricted to cancers arising in the colon rather
than in the colon and rectum combined.
DISCUSSION
APC I1307K polymorphism is a common risk factor
for colorectal cancer in the Jewish population, and it
also increases the risk for colorectal adenomas. Al-
though originally described in Ashkenazi Jews, we
have demonstrated that approximately 3 percent of
non-Ashkenazi Jews and 3 percent of Arab popula-
tions also carry this polymorphism.14 This estimate is
higher than previous reports of a prevalence of less
than 2 percent in non-Ashkenazi Jewish popula-
tions.3,15 Another small study reported that this poly-
morphism was not found in any Arabs or non-
Ashkenazi Jews with colorectal cancer other than in
Jews from Yemen in which the mutation prevalence
was reported to be extremely high.4
Our study identified a higher prevalence of adeno-
mas among carriers of APC I1307K with colorectal
cancer; this is in line with a previous study that re-
ported an elevated frequency of this polymorphism in
Ashkenazi Jews with adenomatous polyps but not
with hyperplastic polyps.10 Hyperplastic polyps were
rarely mentioned in our pathology reports of cancer
specimen, but this does not necessarily reflect a true
lack of these polyps. While we found more adenomas
with a tubular component, the phenotypic features of
the adenomas in another study of Ashkenazi Jews
were indistinguishable between I1307K carriers and
noncarriers. Our data suggesting that tubular and tu-
bulovillous adenomas are overrepresented among
APC I1307K carriers is driven by differences that were
appreciated predominantly in non-Ashkenazi Jews
and should be replicated in additional studies. The
accuracy of our findings relies on information pro-
vided by the pathologist and not on colonoscopy
findings. Such data are dependent on the size of the
Table 2.


























Jews 817 51.3% 49.7 33.6% 33.7 0.03
39/76 (33.7,65.8) 249/741 (29.5,37.9)
Ashkenazi 633 47.9% 46.0 33.3% 32.6 (0.06)
34/71 (30.1,61.8) 187/562 (27.9,37.4)
Males 331 51.4% 46.8 35.8% 34.4 (0.15)
18/35 (24.3,69.3) 106/296 (27.8,41.1)
Females 302 44.4% 43.2 30.5% 29.9 (0.13)
16/36 (21.1,65.4) 81/266 (23.3,36.5)
Non-Ashkenazi 184 100.0% 55.4 34.6% 20.8 (0.25)
5/5 (0,155.3) 62/179 (11.0,30.6)
Males 94 100.0% 55.4 40.0% 42.5 (0.34)
4/4 (0,115.5) 36/90 (28.1,57.0)
Females 90 100.0% 40.6 29.2% 31.8 (0.42)
1/1 (0,120.4) 26/89 (18.2,45.5)
Total (Jews and non-Jews) 896 51.3% 49.9 32.6% 25.8 0.002
40/78 (34.2,65.8) 268/822 (22.3,29.4)
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resected sample, assumed to be similar between cases
because it usually stemmed from hemicolectomy.
The literature provides equivocal evidence regard-
ing the relationship of APC I1307K to colorectal ade-
nomas. A community survey of 189 Ashkenazi Jews
with a personal or family history of colorectal cancer
who underwent a single colonoscopic evaluation did
not find any significant differences in polyp size, mul-
tiplicity, location, or degree of villosity between car-
riers and noncarriers.16 In contrast, APC I1307K mu-
tations and APC E1317Q were commonly found in a
study of patients with multiple colorectal adenomas,
leading the authors to recommend screening patients
with these mutations.11 The study of 183 Ashkenazi
patients with polyps reported by Syngal et al. dem-
onstrated that APC I1307K was more common in Ash-
kenazi Jewish patients with adenomas than in patients
with hyperplastic polyps.10 This polymorphism was
similarly overrepresented in the 72 Ashkenazi patients
with adenomas reported by Gryfe et al. in their large
cohort of unselected Ashkenazi Jewish subjects with
adenomatous polyps and/or colorectal cancer. The
authors concluded that the APC I1307K variant leads
to increased adenoma formation.2
Table 3.
Proportion With Adenomas, by Histologic Type Among Carriers of the APC I1307K Polymorphism
Type of Adenoma Carriers Noncarriers P-Value
All Jews
Tubular 25.0 15.7 0.04
19/76 116/741
Tubulovillous 11.8 8.4 (0.31)
9/76 62/741
Villous 5.3 4.2 (0.66)
4/76 31/741
Any tubular component 35.5 22.0 0.008
27/76 163/741
Any villous component 17.1 11.9 (0.19)
13/76 88/741
Ashkenazi Jews
Tubular 19.7 15.3 (0.34)
14/71 86/562
Tubulovillous 12.7 8.0 (0.18)
9/71 45/562
Villous 4.2 4.6 (1.00)
3/71 26/562
Any tubular component 31.0 21.2 0.06
22/71 119/562
Any villous component 16.9 12.1 (0.25)
12/71 68/562
Non-Ashkenazi Jews
Tubular 100.0 16.8 <0.001
5/5 30/179
Tubulovillous 0.0 9.5 (1.00)
0/5 17/179
Villous 20.0 2.8 (0.15)
1/5 5/179
Any tubular component 100.0 24.6 0.001
5/5 44/179
Any villous component 20.0 11.2 (0.46)
1/5 20/179
Total (Jews and non-Jews)
Tubular 25.6 15.6 0.02
20/78 128/822
Tubulovillous 11.5 8.0 (0.28)
9/78 66/822
Villous 5.1 4.0 (0.55)
4/78 33/822
Any tubular component 37.2 23.6 0.005
29/78 194/822
Any villous component 16.7 12.0 (0.17)
13/78 99/822
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Together with reproducible evidence that APC
I1307K is a risk factor for colorectal cancer, our data
suggest that colonoscopic surveillance for colorectal
adenomas and cancer may be warranted in I1307K
carriers, even in the absence of other identifiable risk
factors. Colonoscopic screening for adenomas in this
genetic subgroup carries a higher potential for colo-
rectal cancer prevention than in an average risk popu-
lation. Given the size of the APCI1307K carrier Jewish
population, such screening could potentially translate
into a meaningful effect on colorectal cancer inci-
dence.
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